A 🧵 on our recent study on surveillance for IR-NMIBC @EurUrolOncol https://t.co/trmFp9Yd0y There is limited evidence on follow-up for IR-NMIBC. We used data from >2000 primary Ta–T1 NMIBC to stratify IR-NMIBC by recurrence risk and propose a risk-adapted follow-up approach.

BCG-unresponsive NMIBC trials feel confusing—and inconsistent EFS reporting is a big reason why We analyze the CIS+ cohorts of 4-FDA registration trials to provide interpretable EFS estimates 🧵👇 @Annals_Oncology @tompowles1 @JoshMeeks @wandering_gu https://t.co/UVlffMc8qY

Great weekend for the @EAU_YAUrotheli group in Warsaw! 🇵🇱 Some members joined the Uro-Onco and Robotics Sections meeting hosted by @PTUweb. A highly valuable platform for sharing research and reinforcing our collaborative efforts. Fantastic energy and knowledge exchange! 🤝

Honoured to join the Polish Uro-Onc meeting in Warsaw with two talks on NMIBC. Grateful to the organisers for the outstanding scientific level and organisation. A great visit to a beautiful city and hopefully the start of new collaborations @PTUweb⁩ ⁦@CEJUrol @EAU_YAUrotheli

Fantastic #bladdercancer session at #EMUC2025 with a brilliant discussion and a truly stellar panel. So much is chanhing with new treatments, and urologists need to be ready for what’s coming next. @Uroweb

Great brainstorming session today at #EMUC25 focused on advancing the most current insights in urothelial carcinoma research 🚀

Proud to stand with the entire @EAUYAUrology community here at #EMUC25 in Prague! 🇨🇿 A fantastic group of young clinicians and researchers pushing GU oncology forward, together. @Uroweb @myESMO @ESTRO_RT

It was a real pleasure to speak at the annual Congress of the Société Internationale d’Urologie @SIU_urology in Edinburgh. Excellent scientific sessions and inspiring discussions with an outstanding faculty. #SIU2025Edinburgh #bladdercancer @istitutotumori

Sure hope so! - but we’ve been down this road before, and unfortunately patients paid the price when enthusiasm outpaced the evidence. A pCR is only part of the story; the real question is what happens when patients stop systemic therapy and return to “real life” outside a trial

Congrats to @SScagliarini_ for an outstanding Delphi Consensus on Italian priorities in #renalcancer, a truly multidisciplinary discussion tackling key controversial and evolving aspects of care. Great example of collaboration shaping precision oncology! 👏🇮🇹

#RccConsensusConference Italian Priorities in RCC A modified Delphi Consensus Statements - Positive margins after partial resection - Residual tumor thrombosis - Radiotherapy to the primary tumor - Prognostic nomograms -Oligoprogression @AIOMtweet @IKCCorg

Back from #ERUS2025 in London! Amazing to reconnect with friends & colleagues and attend such a high-level meeting with live surgery by the best robotic surgeons worldwide. Thrilled about my debut with YAU Robotics & the inspiring J-ERUS session led by new chair @driuliaandras!🤖

Thrilled to share that my friend and former @HumanitasMilano colleague @EdoardoBeatrici received the 3rd Best Video Award at #ERUS2025 in London! 🏆 A well-deserved recognition of his excellent work and a pleasure to have collaborated with him on this project @Uroweb

On behalf of the IBCG Board, thank you to all who joined us from across the globe for #IBCG25 Your expertise, energy, and commitment made this a true success. It was a joy to see familiar faces and new ones alike, and to share in the lively debates and genuine camaraderie that

The best part about @IBCG_BladderCA besides advancing science & disseminating knowledge is putting the patient in the center of everything. Kicking off day 2 with panel of patient advocates discussing their patient perspectives. @WorldBladderCan @BladderCancerUS @UroDocAsh

I’m truly honored to have received the IBCG TravelAward25 My thanks to the panel and to IBCG members. #IBCG25 is the place to be for anyone dedicated to advancing BC research and care Grateful to learn and collaborate with inspiring colleagues shaping the future of #bladdercancer

Honored to join my first #IBCG meeting and to return to Houston! Excited to learn, share, and collaborate with world experts to advance real-world solutions for #BladderCancer patients. #IBCG25

Thrilled to welcome over 100 global experts and patient advocates to Houston for #IBCG25! Together we’ll focus on two crucial goals: integrating bladder cancer biomarkers into clinical practice, and developing tools to better monitor and address local bladder toxicity - guided

As we get ready for #IBCG25, we’d like to welcome our new members - bringing fresh perspectives, expertise, and energy to our global mission. Your voices and vision will help shape the future of bladder cancer care through collaboration, innovation, and shared purpose. Welcome!

🎊The 2nd Edition of the Special Issue 'Urologic Oncology: Biomarkers, Diagnosis, and Management' is now online! 🧑‍⚕️Guest Editor: Dr. Roberto Contieri @RobertoContieri #urology #Diagnostic Check out more details and submit by 30 June 2026 at https://t.co/tSPuYTFxl6

Our SEER-based study shows that pts with cN+ M0 bladder cancer who received chemotherapy + radical cystectomy had better CSS and OS compared to those who had chemoradiation. The 5-yr OS was only 25%. https://t.co/sjsZOlStnf @Pietro9609 @UroMoschini @BenjaminPradere @SBoorjian